Cell and Gene Therapy CRO Market Size was valued at USD 1.46 Bn in 2023 and is predicted to reach USD 2.43 Bn by 2031 at a 6.7% CAGR during the forecast period for 2024-2031.
Cell and gene therapy involves manipulating a patient's cells to introduce, remove, or alter specific genes in order to correct genetic problems. By getting to the bottom of hereditary disorders like cystic fibrosis and cancer, this treatment approach has promise. Clinical trials have revealed promising outcomes, and it holds potential for individualized therapy. Correction of genetic defects or modification of gene expression to improve cardiac and vascular function is the main goal of gene therapy in the treatment of coronary artery disease.
One approach to cell and gene therapy that makes use of viral vectors is the delivery of therapeutic genes to cells in the cardiovascular system. Increased awareness of gene therapy and substantial investments in research and development are driving forces behind the cell and gene therapy CRO market's rapid expansion. Cell and gene therapy is anticipated to have a significant impact on the cancer treatment industry due to several variables, including rising cancer rates, ethical acceptance of the treatment, and more support from the government. The rising incidence of long-term diseases, including cancer, rare genetic disorders affecting a wide range of uncommon diseases, and others, is a major force propelling the gene therapy market forward.
However, the market growth is hampered by the high-cost criteria for the safety and health of the call and gene therapy market. The product's inability to prevent fog in environments with dramatic temperature fluctuations or high call and gene therapy due to complex manufacturing, long clinical trials, strict regulatory requirements, and gene therapy incurs high R&D expenses. These monetary roadblocks cause businesses trouble because they reduce their investment potential, which in turn reduces development and market accessibility. If gene therapy is to advance and become more accessible to patients, the prohibitive expense must be addressed. Due to the COVID-19 pandemic, which has affected the worldwide market and forced the closure of numerous factories in an effort to protect their personnel from contracting the virus, the expansion of the industry may be hindered.
Cell and gene therapy CRO market is segmented based on type of cell therapy, stage of development, type of genetic modification, therapeutic area, and end-users. Based on type, the market is segmented into Ex vivo and In vivo. Based on the stage of development, the market is segmented into discovery, preclinical, and clinical. Based on therapeutic area, the market is segmented into blood disorders, cardiovascular disorders, dermatological disorders, immunological disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, neurological disorders, oncological disorders, rare diseases, and other disorders. On the basis of type of cell therapy, market segmented into CAR-NK, CAR-T, TCR-T, and others. Type of genetic modification includes ex-vivo and in-vivo. By end-users, the market is segmented into industry players and non-industry players.
The cardiovascular disorders segment of the cell and gene therapy CRO market is expected to hold a major global market share in 2023. The need for pharmaceutical compounds to treat arterial and cardiovascular ailments is rising globally. With more and more people suffering from heart conditions, the pharmaceutical chemicals market is seeing growth in cardiovascular applications.
Cell and gene therapies are groundbreaking treatments, but require rigorous testing before reaching patients. Due to this, the clinical segment dominates the CRO market in this field. CROs, or Contract Research Organizations, handle clinical trials for pharmaceutical and biotech companies. These trials involve multiple stages with increasing numbers of participants to assess safety and effectiveness. CROs with clinical expertise understand the strict regulations for cell and gene therapies and guide their clients through the approval process. With the focus on safety and navigating regulations, the clinical segment is crucial. Even though the gene therapy segment itself is projected to grow, the clinical segment will likely remain on top as companies develop and test these innovative therapies.
The North American cell and gene therapy CRO market is expected to register the highest market share in revenue in the near future. It can be attributed to the prevalence of chronic diseases, high and rising healthcare expenditure, an advanced healthcare infrastructure, available reimbursements, and the presence of major market players. In addition, Asia Pacific is projected to grow rapidly in the global cell and gene therapy in market due to the huge amount of registered clinical trials linked to the treatments. The significant focus on government funding and reforms is another factor expected to contribute to expanding the region's chimeric antigen gene therapy market in the coming years.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1.46 Bn |
|
Revenue Forecast In 2031 |
USD 2.43 Bn |
|
Growth Rate CAGR |
CAGR of 6.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Cell Therapy, By Stage of Development, By Type of Genetic Modification, By Therapeutic Area, By End-users and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Altasciences, Allucent, CMIC, Labcorp, Linical, Medpace, PPD, Precision for Medicine, QPS, Syneos Health, CMED, ICON, Pharmalex, and Novotech. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy CRO Market Snapshot
Chapter 4. Global Cell and Gene Therapy CRO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type of Cell Therapy Estimates & Trend Analysis
5.1. by Type of Cell Therapy & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type of Cell Therapy:
5.2.1. CAR-NK
5.2.2. CAR-T
5.2.3. TCR-T
5.2.4. Others
Chapter 6. Market Segmentation 2: by Type of Genetic Modification Estimates & Trend Analysis
6.1. by Type of Genetic Modification& Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type of Genetic Modification:
6.2.1. Ex vivo
6.2.2. In vivo
Chapter 7. Market Segmentation 3: by Stage of Development Estimates & Trend Analysis
7.1. by Stage of Development & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Stage of Development:
7.2.1. Discovery
7.2.2. Preclinical
7.2.3. Clinical
Chapter 8. Market Segmentation 4: by Therapeutic Area Estimates & Trend Analysis
8.1. by Therapeutic Area & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Therapeutic Area:
8.2.1. Blood Disorders
8.2.2. Cardiovascular Disorders
8.2.3. Dermatological Disorders
8.2.4. Immunological Disorders
8.2.5. Infectious Diseases
8.2.6. Metabolic Disorders
8.2.7. Musculoskeletal Disorders
8.2.8. Neurological Disorders
8.2.9. Oncological Disorders
8.2.10. Rare Diseases
8.2.11. Other disorders
Chapter 9. Market Segmentation 5: by End-User Estimates & Trend Analysis
9.1. by End-User & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-User:
9.2.1. Industry Players
9.2.2. Non-Industry Players
Chapter 10. Cell and Gene Therapy CRO Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Cell Therapy, 2019-2031
10.1.2. North America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Genetic Modification,2019-2031
10.1.3. North America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development ,2019-2031
10.1.4. North America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area ,2019-2031
10.1.5. North America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
10.1.6. North America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
10.2. Europe
10.2.1. Europe Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Cell Therapy, 2019-2031
10.2.2. Europe Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Genetic Modification ,2019-2031
10.2.3. Europe Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development ,2019-2031
10.2.4. Europe Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031
10.2.5. Europe Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
10.2.6. Europe Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
10.3. Asia Pacific
10.3.1. Asia Pacific Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Cell Therapy, 2019-2031
10.3.2. Asia Pacific Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Genetic Modification,2019-2031
10.3.3. Asia-Pacific Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development ,2019-2031
10.3.4. Asia Pacific Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031
10.3.5. Asia Pacific Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
10.3.6. Asia Pacific Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
10.4. Latin America
10.4.1. Latin America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Cell Therapy, 2019-2031
10.4.2. Latin America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Genetic Modification, 2019-2031
10.4.3. Latin America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development ,2019-2031
10.4.4. Latin America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area ,2019-2031
10.4.5. Latin America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
10.4.6. Latin America Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Cell Therapy, 2019-2031
10.5.2. Middle East & Africa Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Type of Genetic Modification, 2019-2031
10.5.3. Middle East & Africa Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2019-2031
10.5.4. Middle East & Africa Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area ,2019-2031
10.5.5. Middle East & Africa Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
10.5.6. Middle East & Africa Cell and Gene Therapy CRO Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Altasciences
11.2.2. Allucent
11.2.3. CMIC
11.2.4. Labcorp
11.2.5. Linical
11.2.6. Medpace
11.2.7. PPD
11.2.8. Precision for Medicine
11.2.9. QPS
11.2.10. Syneos Health
11.2.11. CMED
11.2.12. ICON
11.2.13. Pharmalex
11.2.14. Novotech
11.2.15. Other Prominent Players
Cell and Gene Therapy CRO Market- By Type of Cell Therapy
Cell and Gene Therapy CRO Market- By Type of Genetic Modification
Cell and Gene Therapy CRO Market-By Stage of Development
Cell and Gene Therapy CRO Market-By Therapeutic Area
Cell and Gene Therapy CRO Market-By End-Users
Cell and Gene Therapy CRO Market-By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
